Skip to main content

Table 1 Participant characteristics. Table showing participant characteristics for patients with immune-mediated inflammatory disorder (IMIDs) treated with immunosuppressants (ISP), IMID patients without ISP and healthy controls

From: Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity

 

ISP (N = 193)

No ISP (N = 67)

Healthy controls (N = 46)

Age

 Years, mean (SD)

43.8 (14.2)

46.2 (13.4)

45.6 (13.0)

Sex, No (%)

 Female

120 (62.2)

44 (65.7)

28 (60.9)

 Male

73 (37.8)

23 (34.3)

18 (39.1)

BMI

 Mean (SD)

25.6 (4.6)

25.1 (4.4)

24.4 (3.4)

IMID diagnosis, No (%)

 Rheumatic disease

  Rheumatoid arthritis

25 (13.0)

0 (0)

NA

  SLE

16 (8.3)

4 (6.0)

NA

  Spondylarthritis

11 (5.7)

2 (3.0)

NA

  Other rheumatic disease

4 (2.0)

1 (1.5)

NA

 Gastrointestinal disease

  Crohn's disease

32 (16.6)

11 (16.4)

NA

  Ulcerating colitis

19 (9.8)

3 (4.5)

NA

  Other IBD

3 (1.6)

1 (1.5)

NA

 Neurological disease

  MS and NMO

31 (16.1)

17 (25.4)

NA

  Inflammatory neuropathies and myopathies

12 (6.2)

0 (0)

NA

  Myasthenia gravis

11 (5.7)

3 (4.5)

NA

 Dermatological disease

  Atopic dermatitis

12 (6.2)

0 (0)

-

  Other dermatological

17 (8.8)

23 (34.3)

NA

 Other IMID

  Other

0 (0)

2 (3.0)

NA

Medication group, No (%)

 Anti-CD20

14 (7.3)

0 (0)

0 (0)

 Anti-TNF

49 (25.4)

0 (0)

0 (0)

 Other ISP

130 (67.4)

0 (0)

0 (0)

SARS-CoV-2 infection diagnosis, No (%)

 PCR test positive

189 (97.9)

63 (94.0)

44 (95.7)

 Antigen test positive

4 (2.1)

4 (6.0)

2 (4.4)

COVID-19 severity, No (%)a

 Asymptomatic

12 (6.2)

2 (3.0)

0 (0)

 Mild

171 (88.6)

63 (94.0)

45 (100)

 Moderate (hospitalization with oxygen)

5 (2.6)

1 (1.5)

0 (0)

 Moderate (hospitalization without oxygen)

4 (2.1)

0 (0)

0 (0)

 Severe (ICU admission)

1 (0.5)

1 (1.5)

0 (0)

 Death

0 (0)

0 (0)

0 (0)

Time from infection to sample

 Days, median [IQR]

165 [96.3–224]

199 [90.5–233]

189 [85.5–230]

  1. BMI Body mass index, IBD Inflammatory bowel disease, ICU Intensive-care unit, IMID Immune-mediated inflammatory disorder, ISP Immunosuppressant, MS Multiple sclerosis, NMO Neuromyelitis optica, PCR Polymerase chain reaction, SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2, SLE Systemic lupus erythematosus
  2. aMissing due to withdrawn informed consent before COVID-19 severity could be assessed from medical records: 1/46 (2.2%) of healthy controls